| 1 |
Garcia-Manero G. Myelodysplastic syndromes:2023 update on diagnosis, risk-stratification, and management[J]. Am J Hematol, 2023, 98(8):1307-1325.
|
| 2 |
National Cancer Institute. SEER*Explorer:Myelodysplastic syndromes (MDS) recent trends in age-adjusted incidence rates, 2001-2022[EB/OL]. 2025-11-10.
URL
|
| 3 |
Li H, Hu F, Gale RP, et al. Myelodysplastic syndromes[J]. Nat Rev Dis Primers, 2022, 8(1):74.
|
| 4 |
Qimudesiren, Yin W, Wang Y, et al. Hematopoietic stem cell transplantation in the management of myelodysplastic syndrome:a retrospective, current, and future perspective[J]. Cell Transplant, 2024, 33:9636897241284283.
|
| 5 |
Bischof L, Ussmann J, Platzbecker U, et al. Allogeneic stem cell transplantation for MDS-clinical issues, choosing preparative regimens and outcome[J]. Leuk Lymphoma, 2025, 66(8):1362-1375.
|
| 6 |
Hosono N. Genetic abnormalities and pathophysiology of MDS[J]. Int J Clin Oncol, 2019, 24(8):885-892.
|
| 7 |
Bruzzese A, Martino EA, Mendicino F, et al. Myelodysplastic syndromes del(5q):pathogenesis and its therapeutic implications[J]. Eur J Haematol, 2024, 112(6):860-869.
|
| 8 |
Nakajima H. Molecular pathogenesis and treatment of myelodysplastic syndromes[J]. Intern Med, 2021, 60(1):15-23.
|
| 9 |
Nawas MT, Kosuri S. Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML[J]. Blood Adv, 2024, 8(3):553-561.
|
| 10 |
Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation[J]. J Clin Oncol, 2014, 32(25):2691-2698.
|
| 11 |
张玉培, 谢新生, 石雅洁, 等. 异基因造血干细胞移植治疗ASXL1基因突变的骨髓增生异常综合征患者的效果[J]. 实用医学杂志, 2023, 39(23):3087-3092.
|
| 12 |
洪明华, 常春康. 骨髓增生异常肿瘤的骨髓微环境促进疾病发生发展的机制[J]. 中华血液学杂志, 2023, 44(4):350-352.
|
| 13 |
李凡, 何海萍, 张丽华, 等. 骨髓增生异常综合征患者来源间充质干细胞的最新研究进展[J]. 中国实验血液学杂志, 2022, 30(4):1286-1290.
|
| 14 |
Li K, Shi H, Zhang B, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer[J]. Signal Transduct Target Ther, 2021, 6(1):362.
|
| 15 |
Krüger T, Wehner R, Herbig M, et al. Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease[J]. Front Immunol, 2022, 13:1005554.
|
| 16 |
Rodriguez-Sevilla JJ, Colla S. Inflammation in myelodysplastic syndrome pathogenesis[J]. Semin Hematol, 2024, 61(6):385-396.
|
| 17 |
Hellström-Lindberg E, van de Loosdrecht A. Erythropoiesis stimulating agents and other growth factors in low-risk MDS[J]. Best Pract Res Clin Haematol, 2013, 26(4):401-410.
|
| 18 |
List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion[J]. N Engl J Med, 2006, 355(14):1456-1465.
|
| 19 |
Toma A, Kosmider O, Chevret S, et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion[J]. Leukemia, 2016, 30(4):897-905.
|
| 20 |
Zhou L, McMahon C, Bhagat T, et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase[J]. Cancer Res, 2011, 71(3):955-963.
|
| 21 |
Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS):a multicentre, open-label phase 2 dose-finding study with long-term extension study[J]. Lancet Oncol, 2017, 18(10):1338-1347.
|
| 22 |
Kröger N. Treatment of high-risk myelodysplastic syndromes[J]. Haematologica, 2025, 110(2):339-349.
|
| 23 |
Wattel E, De Botton S, Luc Laï J, et al. Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy:incidence of long-term survivors and outcome of partial responders[J]. Br J Haematol, 1997, 98(4):983-991.
|
| 24 |
Tentori CA, Gregorio C, Robin M, et al. Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes[J]. J Clin Oncol, 2024, 42(24):2873-2886.
|
| 25 |
Ramanathan R, Xie Y, Badar T, et al. Contemporary management paradigms and emerging therapeutics for myelodysplastic syndromes/neoplasms[J]. Br J Haematol, 2025, 206(6):1571-1581.
|
| 26 |
DeFilipp Z, Ciurea SO, Cutler C, et al. Hematopoietic cell transplantation in the management of myelodysplastic syndrome:an evidence-based review from the American society for transplantation and cellular therapy committee on practice guidelines[J]. Transplant Cell Ther, 2023, 29(2):71-81.
|
| 27 |
Schetelig J, de Wreede LC, van Gelder M, et al. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia[J]. Leukemia, 2019, 33(3):686-695.
|
| 28 |
刘子闲, 吕梦楠, 王茜茜, 等. 异基因造血干细胞移植治疗骨髓增生异常综合征的预后因素分析[J]. 中华血液学杂志, 2019, 40(6): 484-489.
|
| 29 |
Sébert M, Thepot S, Cluzeau T, et al. Transplantation in patients with lower-risk MDS:a prospective phase 2 trial based on donor availability[J]. Blood Adv, 2026, 10(2):494-504.
|
| 30 |
Nakamura R, Saber W, Martens MJ, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome[J]. J Clin Oncol, 2021, 39(30):3328-3339.
|
| 31 |
Little AM, Akbarzad-Yousefi A, Anand A, et al. BSHI guideline:HLA matching and donor selection for haematopoietic progenitor cell transplantation[J]. Int J Immunogenet, 2021, 48(2):75-109.
|
| 32 |
Timofeeva OA, Philogene MC, Zhang QJ. Current donor selection strategies for allogeneic hematopoietic cell transplantation[J]. Hum Immunol, 2022, 83(10):674-686.
|
| 33 |
Kunacheewa C, Ungprasert P, Phikulsod P, et al. Comparative efficacy and clinical outcomes of haploidentical stem cell transplantation to other stem sources for treatment in acute myeloid leukemia and myelodysplastic syndrome patients:a systematic review and meta-analysis[J]. Cell Transplant, 2020, 29:963689720904965.
|
| 34 |
Raj K, Eikema DJ, Sheth V, et al. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes:report from the chronic malignancies working party of EBMT[J]. Blood Cancer J, 2022, 12(9):140.
|
| 35 |
Kim HT, Ho VT, Nikiforow S, et al. Comparison of older related versus younger unrelated donors for older recipients of allogeneic hematopoietic cell transplantation with acute myeloid leukemia or myelodysplastic syndrome:a large single-center analysis[J]. Transplant Cell Ther, 2024, 30(7):687.e1-687.e13.
|
| 36 |
Arcuri LJ, Ribeiro AAF, Hamerschlak N, et al. Posttransplant cyclophosphamide beyond haploidentical transplantation[J]. Ann Hematol, 2024, 103(5):1483-1491.
|
| 37 |
Mehta RS, Sparapani RA, Kanakry CG, et al. Unrelated donor age and recipient outcomes after posttransplant cyclophosphamide vs conventional prophylaxis[J]. JAMA Oncol, 2025, 12(1):28-37.
|
| 38 |
Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation:one size does not fit all[J]. Blood, 2014, 124(3):344-353.
|
| 39 |
Scott BL, Pasquini MC, Fei M, et al. Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial[J]. Transplant Cell Ther, 2021, 27(6):483.e1-483.e6.
|
| 40 |
Henoun Loukili N, Gras L, Koster L, et al. Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT):a study on behalf of the chronic malignancies working party of the EBMT[J]. Bone Marrow Transplant, 2025, 60(11):1487-1495.
|
| 41 |
Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation[J]. N Engl J Med, 2017, 376(6):536-547.
|
| 42 |
Xuan L, Dai M, Jiang E, et al. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation:an open-label, multicentre, randomised, phase 3 trial[J]. Lancet Haematol, 2023, 10(3):e178-e190.
|
| 43 |
Wei Y, Luan S, Wang L, et al. Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes[J]. Front Immunol, 2025, 16:1586512.
|
| 44 |
Wedge E, Sengeløv H, Hansen JW, et al. Improved outcomes after allogenic hematopoietic stem cell transplantation with fludarabine/treosulfan for patients with myelodysplastic syndromes[J]. Biol Blood Marrow Transplant, 2020, 26(6):1091-1098.
|
| 45 |
Yu S, Zhuang W, Gao S, et al. Impact of decitabine conditioning on allo-HSCT outcomes in AML and intermediate-to-high-risk MDS patients in remission[J]. Cancer Med, 2025, 14(14):e71081.
|
| 46 |
Kolloch L, Berning P, Albring JC, et al. Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan-or TBI-based conditioning[J]. Bone Marrow Transplant, 2025, 60(11):1533-1536.
|
| 47 |
Albanyan O, Elmariah H, Kalos D, et al. Melphalan dose in combination with fludarabine affects gastrointestinal toxicity and graft-versus-host disease after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndromes[J]. Transplant Cell Ther, 2024, 30(11):1090.e1-1090.e10.
|
| 48 |
Zugasti I, Lopez-Guerra M, Castaño-Díez S, et al. Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant:a GESMD study[J]. Exp Hematol Oncol, 2025, 14(1):61.
|
| 49 |
Zeidan AM, Borate U, Pollyea DA, et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes[J]. Am J Hematol, 2023, 98(2):272-281.
|
| 50 |
Khanam R, Shahzad M, Chaudhary SG, et al. Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes:a systematic review and meta-analysis[J]. Leuk Lymphoma, 2022, 63(11):2671-2678.
|
| 51 |
Assouline S. Decitabine plus cedazuridine and venetoclax:the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia[J]. Lancet Haematol, 2024, 11(3):e170-e171.
|
| 52 |
Schroeder JC, Mix L, Faustmann P, et al. Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome[J]. Bone Marrow Transplant, 2024, 59(9):1332-1334.
|
| 53 |
Vago L. Clonal evolution and immune evasion in posttransplantation relapses[J]. Hematology Am Soc Hematol Educ Program, 2019, 2019(1):610-616.
|
| 54 |
Yerushalmi Y, Shem-Tov N, Danylesko I, et al. Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation[J]. Haematologica, 2023, 108(7):1782-1792.
|
| 55 |
Guillaume T, Thépot S, Peterlin P, et al. Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome[J]. Transplant Cell Ther, 2021, 27(10):839.e1-839.e6.
|
| 56 |
Tong X, Li M, Jin J, et al. Cladribine-and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome[J]. Int J Cancer, 2023, 152(10):2123-2133.
|
| 57 |
Wei Y, Wang L, Zhu C, et al. A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation[J]. Med Oncol, 2023, 40(2):77.
|
| 58 |
Chiusolo P, Malagola M, Giglio F, et al. Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT[J]. Bone Marrow Transplant, 2026, 61(1):101-103.
|
| 59 |
Parks K, Diebold K, Salzman D, et al. Low-dose decitabine plus venetoclax as post-transplant maintenance for high-risk myeloid malignancies[J]. EJHaem, 2024, 5(3):560-564.
|
| 60 |
Santini V, Stahl M, Sallman DA. TP53 mutations in acute leukemias and myelodysplastic syndromes:insights and treatment updates[J]. Am Soc Clin Oncol Educ Book, 2024, 44(3):e432650.
|
| 61 |
DeFilipp Z, Chen YB. How I treat with maintenance therapy after allogeneic HCT[J]. Blood, 2023, 141(1):39-48.
|